WuXi Biologics Forecasts Strong 2025 Profit Growth on Expanded Services and Efficiency Gains

Wuxi Biologics (Cayman) ( (HK:2269) ) has shared an update.

WuXi Biologics (Cayman) Inc. has issued a positive profit alert, indicating that for the year ended December 31, 2025, revenue is expected to rise about 16.7% to RMB21.79 billion, with gross margin expanding by roughly five percentage points to 46%. Adjusted gross profit is projected to climb 25.5% to around RMB10.64 billion, while net profit and profit attributable to shareholders are seen increasing by about 45.3% and 46.3% to RMB5.73 billion and RMB4.91 billion, respectively.

The company also expects its non-IFRS adjusted net profit to grow approximately 22% to RMB6.59 billion, reflecting contributions from its “Follow and Win the Molecule” strategy, an expanded spectrum of biologics services and rising research revenues. Improved capacity utilization, including ramp-up of a European manufacturing facility, operational efficiencies from its business system and digitalization, and investment gains further underpin the stronger earnings outlook, signaling reinforced competitive positioning and potential benefits for shareholders.

The most recent analyst rating on (HK:2269) stock is a Hold with a HK$39.00 price target. To see the full list of analyst forecasts on Wuxi Biologics (Cayman) stock, see the HK:2269 Stock Forecast page.

More about Wuxi Biologics (Cayman)

WuXi Biologics (Cayman) Inc. is a Hong Kong-listed contract development and manufacturing organization serving the global biologics industry. The group provides research and discovery, pre-IND development, and clinical and commercial manufacturing services, with growing strengths in bispecific antibodies, antibody-drug conjugates and other cutting-edge biologic technologies.

Average Trading Volume: 34,829,314

Technical Sentiment Signal: Buy

Current Market Cap: HK$155.9B

See more data about 2269 stock on TipRanks’ Stock Analysis page.